NeoGenomics (NASDAQ:NEO) Shares Cross Above 50-Day Moving Average - Here's Why

Key Points

• NeoGenomics shares rose above their 50-day moving average of $17.64, reaching $18.03 and last trading near $17.99 on substantial volume.
• The company beat third-quarter expectations, reporting adjusted earnings of $0.07 per share and revenue of $209.25 million, up 11.3% year over year. Management also raised 2026 revenue guidance to $807 million–$809 million.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $18.17, although NeoGenomics still has a negative net margin and plans a CEO transition in January 2027.

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report)'s share price passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $17.64 and traded as high as $18.03. NeoGenomics shares last traded at $17.99, with a volume of 2,577,279 shares traded.

NeoGenomics News Roundup

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: NeoGenomics reported third-quarter adjusted earnings of $0.07 per share, exceeding the $0.06 analyst consensus. Revenue increased 11.3% year over year to approximately $209.25 million, also beating expectations of $206.70 million. NeoGenomics Third-Quarter Earnings Results
• Positive Sentiment: Management raised its 2026 revenue guidance to $807 million-$809 million, signaling confidence in continued demand and execution. The combination of an earnings beat and higher guidance is likely supporting investor optimism around NeoGenomics’ growth outlook. NeoGenomics Raises 2026 Guidance
• Positive Sentiment: Multiple reports characterized the quarter as a beat on both earnings and revenue, reinforcing the view that NeoGenomics is continuing to expand despite still reporting a negative net margin and negative return on equity. NeoGenomics Q3 Earnings and Revenue Beat Estimates
• Neutral Sentiment: The company plans a CEO transition in January 2027. A planned succession can reduce long-term leadership risk, but investors may watch closely for details on the incoming CEO and whether the new leadership maintains current growth and profitability targets. NeoGenomics Earnings Call Transcript

Analysts Set New Price Targets

Several research firms recently commented on NEO. Weiss Ratings reissued a "sell (d-)" rating on shares of NeoGenomics in a research note on Monday, October 12th. Benchmark raised their target price on shares of NeoGenomics from $11.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, July 24th. TD Cowen reaffirmed a "buy" rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Zacks Research lowered shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a report on Monday, September 28th. Finally, Craig Hallum reissued a "buy" rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $18.17.

NeoGenomics Stock Performance

The stock has a market capitalization of $2.31 billion, a PE ratio of -44.97 and a beta of 1.79. The business has a 50 day moving average price of $17.64 and a 200 day moving average price of $12.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $209.25 million during the quarter, compared to the consensus estimate of $206.70 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%. The company's revenue was up 11.3% on a year-over-year basis. During the same period last year, the company earned $0.03 earnings per share. As a group, equities research analysts expect that NeoGenomics, Inc. will post -0.09 earnings per share for the current year.

Institutional Trading of NeoGenomics

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC raised its stake in NeoGenomics by 118.3% during the 2nd quarter. Squarepoint Ops LLC now owns 222,036 shares of the medical research company's stock valued at $3,240,000 after buying an additional 120,342 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of NeoGenomics during the 2nd quarter valued at $925,000. Bank of New York Mellon Corp bought a new position in shares of NeoGenomics during the 2nd quarter valued at $10,744,000. First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company's stock worth $179,158,000 after buying an additional 2,549,545 shares during the last quarter. Finally, American Capital Management Inc. purchased a new position in shares of NeoGenomics in the 2nd quarter worth $32,648,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

About NeoGenomics

NeoGenomics, Inc NASDAQ: NEO is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company's services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.